RhumbLine Advisers
ABOS icon

RhumbLine Advisers’s Acumen Pharmaceuticals ABOS Stock Holding History

RhumbLine Advisers’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,516
Closed -$50.1K – 4139
2025
Q1 		$50.1K Sell
45,516
-7,560
-14% -$10.8K ﹤0.01% 3576
2024
Q4 		$91.3K Sell
53,076
-35,408
-40% -$85.3K ﹤0.01% 3502
2024
Q3 		$219K Buy
88,484
+36,161
+69% +$98.1K ﹤0.01% 3191
2024
Q2 		$127K Buy
+52,323
New +$167K ﹤0.01% 3438
2022
Q2 		– Sell
-20,273
Closed -$79K – 3085
2022
Q1 		$79K Buy
+20,273
New +$110K ﹤0.01% 2930

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

RhumbLine Advisers's ABOS Position: Q2 2025 in Review

RhumbLine Advisers sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 45,516 shares — an estimated $50.1K sold.

RhumbLine Advisers first reported a position in ABOS in Q1 2022 and held it in 5 quarters. The position peaked at $219K in Q3 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

  • RhumbLine Advisers reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 45,516 Acumen Pharmaceuticals shares in Q2 2025, an estimated $50.1K.
  • RhumbLine Advisers first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • RhumbLine Advisers's Acumen Pharmaceuticals position peaked at $219K in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.